Landmark TAILORx study results make the Oncotype DX Breast Recurrence Score® Assay the new Standard of Care.
The results of the trial showed that 70% of the early-stage breast cancer patients do not benefit from chemotherapy.
read moreThe results of the trial showed that 70% of the early-stage breast cancer patients do not benefit from chemotherapy.
read more“Cancer” is the name given to a group of related diseases.
read moreAngelina Jolie's announcement triggered an increase in the number of people in high risk being screened and this is a very important step so they can minimize the chances of the disease developing.
read moreThe recent results of the Trial Assigning IndividuaLized Options for Treatment – RX (TAILORx) study, the largest clinical trial for breast cancer ever made has shown that most of the women do not benefit from chemotherapy.
read moreCurrent medical treatment boils down to six words: Have disease, take pill, kill something. Physician Siddhartha Mukherjee points to a future of medicine that will transform the way we heal.
read moreΟ έλεγχος και η γενετική παρακολούθηση προλαμβάνει, αντιμετωπίζει και θεραπεύει αποτελεσματικά τον καρκίνο του μαστού
read moreOncotype DX Breast Recurrence Score®, το γενετικό τεστ-εργαλείο για τη μάχη του πρώιμου καρκίνου του μαστού
read moreΝοέμβριος: Μήνας ενημέρωσης κατά του καρκίνου του πνεύμονα
read more